PARP inhibitors such as olaparib, niraparib, rucaparib, and talazoparib are currently being used to treat various cancers (Del Campo et al, 2019; Matulonis et al, 2016; Moore et al, 2018; Swisher et al, 2017), and the natural product nimbolide has been shown to target RNF114, preventing its ubiquitylation and degradation of PARP1 (Li et al, 2023). The gene discussed is RNF114; the disease is cancer.